vamorolone (Agamree)
Jump to navigation
Jump to search
Indications
- treatment of Duchenne muscular dystrophy in patients >= 2 years of age (FDA-approved Oct 2023)
Dosage
- oral suspension: 2-6 mg/kg/day for up to 48 months.
Adverse effects
- less effect on bone health, growth trajectory, & behavior than glucocorticoids
Mechanism of action
- steroidal anti-inflammatory agent
- inhibits proinflammatory NFkB pathways via high-affinity binding to the glucocorticoid receptor
More general terms
References
- ↑ Brooks M FDA Okays Drug for Duchenne Muscular Dystrophy Medscape. October 27, 2023 https://www.medscape.com/viewarticle/997821